MedTrace Logo

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

NCT07205926 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-11-19

No results posted yet for this study

Summary

Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults

Conditions

Interventions

BIOLOGICAL

IVT Shigella-04

Preventative vaccine for Shigella protection against 4 unique serotypes

BIOLOGICAL

Placebo (0.9% saline)

Subjects dosed with 0.9% saline

Sponsors & Collaborators

  • Inventprise Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Inventprise Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-09
Primary Completion
2026-01-26
Completion
2026-08-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07205926 on ClinicalTrials.gov